Drugs / ORP-101
ORP-101
also known as
Buprenorphine dimer
Small molecule targets OPRK1, OPRM1 via inhibition / activation
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04129619 | Nov 2019 → Oct 2021 | irritable bowel syndrome | OrphoMed, Inc. | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04129619 ↗ |
| Known as | Buprenorphine dimer | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594402 ↗ |
| Action | Activate | “Mu opioid receptor partial agonist” CHEMBL4594402 ↗ |
| Action | Inhibit | “Kappa opioid receptor antagonist” CHEMBL4594402 ↗ |
| Modality | Small molecule | — CHEMBL4594402 ↗ |
| Route | Oral | “Oral tablet” NCT04129619 ↗ |
| Target | OPRK1 | “Kappa opioid receptor antagonist” CHEMBL4594402 ↗ |
| Target | OPRM1 | “Mu opioid receptor partial agonist” CHEMBL4594402 ↗ |